4 completed, 1 enrolling by invitation, 1 not yet recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Not yet recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Chao Ji: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313. CM313 (SC), Glucocorticoids - Pemphigus Disease, Pemphigus Vulgaris (PV) | Phase 1 / Phase 2 | Not yet recruiting | Chao Ji | 100 | 2025-10-01 | 2024-10-29 |
| A Real-World Study of Biologic Therapy for Subclinical Psoriatic Arthritis Biologics - Subclinical Psoriatic Arthritis | Enrolling by invitation | Chao Ji | 150 | 2023-11-01 | 2025-03-25 | |
| Efficacy and Safety Evaluation of Anti-CD20 Monoclonal Antibody Combined with Azathioprine and Corticosteroids in the Treatment of Pemphigus Vulgaris Ofatumumab subcutaneous injection - Pemphigus, Pemphigus Vulgaris (PV) | Completed | Chao Ji | 38 | 2023-01-01 | 2024-10-23 | |
| JAK Inhibitors' Efficacy in Bullous Pemphigoid Janus Kinase Inhibitor - Bullous Pemphigoid, Janus Kinase Inhibitor | Completed | Chao Ji | 120 | 2022-01-01 | 2024-09-05 | |
| Biologic Therapy for Generalized Pustular Psoriasis After exclusion of relevant contraindications, participants received subcutaneous ustekinumab/secukinumab therapy. - Generalized Pustular Psoriasis | Completed | Chao Ji | 65 | 2019-07-01 | 2024-04-30 | |
| SJS/TEN or Other Cutaneous Adverse Eevents Induced by Immune Checkpoint Inhibitors (ICIs) vs. Non-ICIs Observational studies do not require intervention - Immune Checkpoint Inhibitor-Induced Dermatitis, Stevens-Johnson Syndrome, Drug-Induced | Completed | Chao Ji | 300 | 2015-01-01 | 2024-07-29 |
Pemphigus (2) · Pemphigoid, Bullous (1) · Psoriasis (1) · Stevens-Johnson Syndrome (1) · Synovitis (1)
Biological Products (1) · Genotype (1) · Glucocorticoids (1) · Janus Kinase Inhibitors (1)
China (5)